Chemoinformaics analysis of 3,4-Dihydroaucubin
| Molecular Weight | 348.348 | nRot | 4 |
| Heavy Atom Molecular Weight | 324.156 | nRig | 16 |
| Exact Molecular Weight | 348.142 | nRing | 3 |
| Solubility: LogS | -0.21 | nHRing | 2 |
| Solubility: LogP | -2.306 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 0 |
| nHetero | 9 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 9 | No. of Arom Bond | 0 |
| nHA | 9 | APOL | 48.271 |
| nHD | 6 | BPOL | 29.285 |
| QED | 0.294 |
| Synth | 4.788 |
| Natural Product Likeliness | 2.742 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.118 |
| HIA | 0.981 |
| CACO-2 | -5.476 |
| MDCK | 0.000421731 |
| BBB | 0.502 |
| PPB | 0.133749 |
| VDSS | 0.322 |
| FU | 0.683811 |
| CYP1A2-inh | 0.001 |
| CYP1A2-sub | 0.036 |
| CYP2c19-inh | 0.005 |
| CYP2c19-sub | 0.103 |
| CYP2c9-inh | 0 |
| CYP2c9-sub | 0.062 |
| CYP2d6-inh | 0.001 |
| CYP2d6-sub | 0.109 |
| CYP3a4-inh | 0.003 |
| CYP3a4-sub | 0.027 |
| CL | 1.427 |
| T12 | 0.52 |
| hERG | 0.018 |
| Ames | 0.258 |
| ROA | 0.115 |
| SkinSen | 0.024 |
| Carcinogencity | 0.679 |
| EI | 0.009 |
| Respiratory | 0.021 |
| NR-Aromatase | 0.01 |
| Antiviral | Yes |
| Prediction | 0.853571 |